Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2024 | $8.00 → $2.00 | Outperform → Neutral | Wedbush |
| 9/22/2023 | $11.00 | Outperform | Wedbush |
| 5/4/2023 | $18.00 | Buy | H.C. Wainwright |
| 12/23/2021 | $25.00 | Buy | HC Wainwright & Co. |
| 8/13/2021 | $30.00 → $27.00 | Outperform | Credit Suisse |
Wedbush downgraded Ikena Oncology from Outperform to Neutral and set a new price target of $2.00 from $8.00 previously
Wedbush initiated coverage of Ikena Oncology with a rating of Outperform and set a new price target of $11.00
H.C. Wainwright resumed coverage of Ikena Oncology with a rating of Buy and set a new price target of $18.00